Giulia Sita

Urinary tract and genital infections with dapagliflozin and empagliflozin across type 2 diabetes, heart failure, and chronic kidney disease: An indication- and sex-stratified disproportionality analysis of eudravigilance reports

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are widely used in type 2 diabetes mellitus (T2DM), chronic heart failure (CHF), and chronic kidney disease (CKD). Although their cardiovascular and renal benefits are well established, urogenital infections remain a relevant safe...